Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Florham Park, NJ, US. The stock last traded at $8.58, up 0.82% on the session, giving a market capitalisation of $694.1M. On trailing twelve-month figures it carries a trailing P/E of -6.70, a net margin of -41.3%. Its beta of 0.50 implies it has historically moved less than the broad market.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc. is most often compared with the following Healthcare names: